We’re excited to continue our advocacy blog series meant to help you take care when it comes to important arthritis health care and coverage issues. If you are just now tuning into this series, check out our previous blog posts on accumulator adjustment programs, pharmacist gag orders, and President Trump’s drug pricing blueprint.
This week we dig in to the world of drug rebates, which are often negotiated between pharmaceutical manufacturers and pharmacy benefit managers (PBMs). Read on to learn more about how drug rebates play a role in the drug supply chain and impact access to medications.
Continue reading TAKE CARE: Advocacy Blog Series
On behalf of the more than 3.6 million New Yorkers (including 18,400 children) with doctor-diagnosed arthritis, the Arthritis Foundation thanks Governor Andrew Cuomo for signing biosimilar legislation into law. The new law, A.7509/S.4788, enhances patient access to new and innovative medications while ensuring that pharmacists are communicating critical and up-to-date medical information about patients to physicians.
Continue reading Victory in New York! Biosimilar Legislation Signed Into Law
Kyleigh O’Brien is an 11-year-old with juvenile arthritis and has testified in front of the Missouri legislature twice this year. Why does she do it?
She wants to be a voice for the estimated 300,000 children in the United States who live with arthritis. Kyleigh has advocated most recently for the passage of Missouri Senate Bill 875 (SB 875), which has now been signed into law by Governor Jay Nixon.
Continue reading Breaking Advocacy News in Missouri – Senate Bill 875 Regarding Biosimilars has Been Signed Into Law!